Carcinoma Endometrioid Ovary pada Struma Ovarii
Abstract
Kanker ovarium merupakan penyebab utama kematian pada wanita yang didiagnosis sebagai kanker ginekologi. Tingginya angka kematian akibat kanker ovarium karena mayoritas kasus bersifat asimptomatik dan skrining yang dilakukan untuk menegakkan diagnosis masih kurang. Hal ini menyebabkan kanker ovarium dikenal sebagai silent killer. Etiologi spesifik kanker ovarium hingga belum diketahui dengan pasti, namun teradapat beberapa faktor risiko yang berperan terhadap terjadinya kanker ovarium. Faktor risiko genetik diduga berkaitan erat dengan kejadian kanker ovarium, diantaranya mutasi pada gen TP53, BRCA1 dan BRCA2. Diagnosis kanker ovarium sulit dilakukan pada stadium dini karena tidak adanya gejala spesifik. Untuk menegakkan diagnosis kanker ovarium dibutuhkan anamnesis, pemeriksaan fisik dan pemeriksaan penunjang seperti CT scan, USG, pemeriksaan tumor marker dan biopsi. Hingga saat ini, pembedahan masih menjadi penatalaksanaan utama bagi kanker ovarium. Pemeriksaan histopatologi juga perlu dilakukan untuk menentukan keganasan, jenis kanker, dan penentuan staging. Kemoterapi adjuvan diberikan pada pasien setelah pembedahan, kecuali jika penyakit hanya terbatas pada ovarium dan pada kanker yang tidak bisa dioperasi. Prognosis kanker ovarium bergantung dari jenis kanker, stadium dan komplikasi yang terjadi. Pada jurnal ini dilaporkan kasus seorang pasien perempuan, berusia 59 tahun dengan carcinoma endometrioid ovary pada struma ovarii.
Keywords
Full Text:
PDFReferences
. Matulonis, U.A., Sood, A.K., Fallowfield L., et al. Ovarian cancer. Nature Reviews Disease Primers. 2016: 2:16061
. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 2011: 61, 69–90
Sant, M. et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur. J. Cancer 2015: 51, 2191–2205
. Lowe, K. A. et al. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol. 2013:130, 107–114
. Kemenkes RI. Situasi Penyakit Kanker. Infodatin (pusat data dan informasi Kementerian Kesehatan RI). 2015. Diunduh dari: http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf
. Bottsford-Miller, J. N., Coleman, R. L. & Sood, A. K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 30, 4026–4034 (2012).
. Furuyo, M. Ovarian Cancer Stroma: Pathophysiology and the Roles in Cancer Development. Cancers (Basel). 2012; 4(3): 701-724
. Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016; 2, 482–490
. Pearce, C. L., Chung, K., Pike, M. C. & Wu, A. H. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009: 115, 531–539.
. Gaitskell, K. et al. Tubal ligation and ovarian cancer risk in a large cohort: substantial variation by histological type. Int. J. Cancer. 2016: 138, 1076–1084
. Terry, K. L. et al. Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev. Res. (Phila) 2013: 6, 811–821
. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016: 66, 7–30
. Sung, P.-L., Chang, Y.-H., Chao, K.-C. & Chuang, C.-M. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol. Oncol. 2014: 133, 147–154
. National Cancer Institute. SEER stat fact sheets: ovarian cancer.2016. Diunduh dari: SEER http://seer.cancer.gov/statfacts/ html/ovary.html
. Goff BA, Mandel LS, Drescher CW, et al. Development of ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007; 109(2):221-7.
Suh-Burgmann E, Kinney W. The value of monitoring of adnexal masses for earlier detection of ovarian cancer. Front Oncol. 2016. 6:25.
. Green AE. Ovarian Cancer. Medscape. 2018. Diunduh dari: https://emedicine.medscape.com/article/255771
. Doubeni CA, Dubeni ARB, Myers AE. Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2015 Jun 1;93(11):937-944.
. Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB. Ovarian Cancer Screening and Early Detection in the General Population. Rev Obstet Gynecol. 2011;4(1):15-21. Diunduh dari: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100094/
. Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007: 31, 161–169
. Coleman RL, Herzog TJ, Chan DW, et al. Validation of second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynaecol. 2016 Mar 9.
. Demir, R. H. & Marchand, G. J. Adnexal masses suspected to be benign treated with laparoscopy. JSLS. 2012; 16, 71–84.
. National Comprehensive Cancer Network. NCCN Clinical Practical Guidelines in Oncology, Ovarian Cancer Including Fallopian Tube Cancerand Primary Peritoneal Cancer. 2017. Diunduh dari http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
. Salani R, Backers FJ, Fung MF et al. Posttreatment surveillance and diagnosis of recurrence in women with gynaecologic oncologist recommendations. Am J Obstet Gynecol. 2011. 204(6):466-78.
. Herrinton LJ, Neslund-Dudas C, Rolnick SJ, et al. Complications at the end of life in ovarian cancer. J Pain Symptom Manage. 2007. 34(3):237-43.
. American Cancer Society. Survival Rates for Ovarian Cancer. 2019. Diunduh dari: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html
DOI: https://doi.org/10.33854/heme.v5i3.1361
Refbacks
- There are currently no refbacks.
Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.